Fig 2.

Subjects treated sequentially with more than 1 biologic. Each box represents 1 subject’s longitudinal timeline across the duration of the study follow-up. Each red “X” on top of the boxes represents 1 exacerbation. The top row of each box shows the individual biologic duration of treatment, the middle row shows duration of daily OCS treatment, and the bottom row shows the duration of antifungal therapy for each subject. Omalizumab in yellow, mepolizumab (Mepo) in blue, benralizumab (Benra) in gray, dupilumab in green, daily OCS treatment in purple, and antifungal treatment in orange. Subject 2 graph is adapted with permission from Lamothe et al.²²